“…Also worth noting are initiatives that aim to harmonize test processing across large laboratory networks [ [53] , [54] , [55] , [56] ]. Finally, we would like to highlight several initiatives that aim to harmonize diagnostic criteria for inclusion of patients into clinical trials, as well as the increasing number of data reports from APS ACTION (AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking) group utilizing “homogeneous” diagnostic criteria [ [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] ]. The recent publication of the latest classification criteria for APS [ 2 ] will hopefully drive further international effort to harmonize research trial enrolment and outcomes.…”